KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease
Redox imbalance and persistent inflammation are the underlying causes of most chronic diseases. Mammalian cells have evolved elaborate mechanisms for restoring redox homeostasis and resolving acute inflammatory responses. One prominent mechanism is that of inducing the expression of antioxidant, ant...
Main Authors: | Sharadha Dayalan Naidu, Albena T. Dinkova-Kostova |
---|---|
Format: | Article |
Language: | English |
Published: |
The Royal Society
2020-06-01
|
Series: | Open Biology |
Subjects: | |
Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.200105 |
Similar Items
-
Anti-Inflammatory Activity of Kurarinone Involves Induction of HO-1 via the KEAP1/Nrf2 Pathway
by: Sakiko Nishikawa, et al.
Published: (2020-09-01) -
The Keap1/Nrf2-ARE Pathway as a Pharmacological Target for Chalcones
by: Matheus de Freitas Silva, et al.
Published: (2018-07-01) -
A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2
by: Lu Qiu, et al.
Published: (2018-07-01) -
Potential Benefits of Nrf2/Keap1 Targeting in Pancreatic Islet Cell Transplantation
by: Alberto Jarrin Lopez, et al.
Published: (2020-04-01) -
Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer
by: Yun Pyo Kang, et al.
Published: (2019-05-01)